Table 3.
Malignancy risk of Bethesda category III/IV thyroid nodules in different TI-RADS.
| Category | Benign (n) | Malignant (n) | Malignancy rate (%) | Recommended malignancy rate (%) | P-value | P for trend2 |
|---|---|---|---|---|---|---|
| ACR-TIRADS | <0.001 | <0.001 | ||||
| 3 | 7 | 0 | 0.0 | 5% | ||
| 4 | 22 | 9 | 29.0 | 5%–20% | ||
| 5 | 10 | 32 | 76.2 | >20% | ||
| K-TIRADS | <0.001 | <0.001 | ||||
| 3 | 7 | 0 | 0.0 | 3%–10% | ||
| 4 | 24 | 13 | 35.1 | 10%–40% | ||
| 5 | 8 | 28 | 77.8 | >60% | ||
| C-TIRADS | <0.001 | <0.001 | ||||
| 3 | 5 | 0 | 0.0 | <2% | ||
| 4A | 17 | 3 | 15.0 | 2%–10% | ||
| 4B | 11 | 8 | 42.1 | 10%–50% | ||
| 4C | 6 | 28 | 82.4 | 50%–90% | ||
| 5 | 0 | 2 | 100 | >90% |